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ABSTRACT Strategies to prevent multidrug-resistant organism (MDRO) infections
are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gas-
trointestinal MDRO expansion. AutoFMT involves banking one’s feces during a
healthy state for later use in restoring gut microbiota following perturbation. This pi-
lot study evaluated the effect of autoFMT on gastrointestinal microbiome taxonomic
composition, resistance gene content, and metabolic capacity after exposure to
amoxicillin-clavulanic acid (Amox-Clav). Ten healthy participants were enrolled. All
received 5 days of Amox-Clav. Half were randomized to autoFMT, derived from stool
collected pre-antimicrobial exposure, by enema, and half to saline enema. Partici-
pants submitted stool samples pre- and post-Amox-Clav and enema and during a
90-day follow-up period. Shotgun metagenomic sequencing revealed taxonomic
composition, resistance gene content, and metabolic capacity. Amox-Clav signiﬁ-
cantly altered gut taxonomic composition in all participants (n  10, P 0.01); how-
ever, only three participants exhibited major changes at the phylum level following
exposure. In the cohort as a whole, beta-lactamase genes were enriched following
Amox-Clav (P 0.05), and predicted metabolic capacity was signiﬁcantly altered
(P 0.01). Species composition, metabolic capacity, and beta-lactamase abundance
returned to pre-antimicrobial exposure state 7 days after either autoFMT or saline
enema (P 0.05, compared to enrollment). Alterations to microbial metabolic capac-
ity occurred following antimicrobial exposure even in participants without substan-
tial taxonomic disruption, potentially creating open niches for pathogen coloniza-
tion. Our ﬁndings suggest that metabolic potential is an important consideration for
complete assessment of antimicrobial impact on the microbiome. AutoFMT was well
tolerated and may have contributed to phylogenetic recovery. (This study has been
registered at ClinicalTrials.gov under identiﬁer NCT02046525.)
IMPORTANCE The spread of multidrug resistance among pathogenic organisms
threatens the efﬁcacy of antimicrobial treatment options. The human gut serves as a
reservoir for many drug-resistant organisms and their resistance genes, and pertur-
bation of the gut microbiome by antimicrobial exposure can open metabolic niches
to resistant pathogens. Once established in the gut, antimicrobial-resistant bacteria
can persist even after antimicrobial exposure ceases. Strategies to prevent
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multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal
microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion.
AutoFMT involves banking one’s feces during a healthy state for later use in restor-
ing gut microbiota following perturbation. This pilot study evaluated the effect of
amoxicillin-clavulanic acid (Amox-Clav) exposure and autoFMT on gastrointestinal
microbiome taxonomic composition, resistance gene content, and metabolic capac-
ity. Importantly, we found that metabolic capacity was perturbed even in cases
where gross phylogeny remained unchanged and that autoFMT was safe and well
tolerated.
KEYWORDS antimicrobial resistance, fecal microbiota transplantation,
metagenomics, microbiome, multidrug resistance
The spread of multidrug resistance among pathogenic organisms has renderedmany treatment options ineffective. The World Health Organization has described
the situation as the dawn of a postantimicrobial era (1). The human gut serves as a
reservoir for many resistant organisms and their resistance genes, and this can lead to
infection in the colonized host and transmission of resistance between commensals
and pathogens (2–8). Once established in the gut, antimicrobial-resistant bacteria can
persist for extended durations even in the absence of additional antimicrobial exposure
(3–9). Novel therapeutic approaches are essential to limit or even reverse colonization
with resistant organisms and the associated risk of infection and transmission between
hosts.
Despite the growing antimicrobial resistance threat, there are no established meth-
ods to effectively reverse the effects of antimicrobial exposure on commensal or
pathogenic bacteria. Several strategies have been proposed for mitigating the threat of
resistance, but each carries risk. For example, using nonabsorbable broad-spectrum
antimicrobials such as rifaximin has been proposed as a method of limiting systemic
resistance selection (10). Using such orally ingested drugs to treat infections localized
to the gastrointestinal tract may indeed limit systemic selection for antimicrobial
resistance; however, this practice still leads to resistance selection in the gut and allows
opportunistic pathogens to gain access in this critical body habitat (11).
A healthy fecal microbiome defends against pathogen and multidrug-resistant
organism (MDRO) invasion through colonization resistance (12). Fecal microbiota trans-
plantation (FMT) has been proposed as a method of restoring the microbiome to a
healthy state after treatment with antimicrobials (13). By displacing infectious or
resistant microbes, the new community can restore species diversity, antimicrobial
susceptibility, and colonization resistance (13). FMT from healthy allogeneic donors
(alloFMT) has been remarkably successful in treating Clostridium difﬁcile infection (CDI)
(13, 14). Some studies indicate that patients who receive alloFMT for CDI may have a
reduction in MDROs in feces as well as infections due to intestinal colonizers (15–21).
However, this approach has been found to inadvertently allow transmission of resis-
tance genes from donor to recipient (22). Donor feces may also transmit pathogens or
pathobionts which are being asymptomatically harbored by the allogeneic donor.
Additionally, microbiota structure varies signiﬁcantly between individuals, and a poor
donor-recipient match may lead to dysbiosis or FMT failure (23–26). Studies to date of
the effects of FMT on the microbiome have primarily relied on 16S ribotype-based
analyses of bacterial taxonomic composition and diversity (27–30). While such studies
have been transformative in demonstrating how well taxonomic compositions match
between FMT donors and recipients over time, they are generally not designed to
illuminate functional changes in the microbiome (29, 30). Accordingly, complementary
approaches are required to enable a higher-resolution understanding of the impact of
FMTs on the composition, dynamics, and transmission of resistance genes and meta-
bolic capacity encoded by the microbiome.
Autologous fecal microbiota transplantation (autoFMT) is a potential method for
restoring the gut to a healthy state while avoiding the risks of donor resistance genes
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and donor-recipient mismatch. AutoFMT involves storage of a healthy person’s fecal
material for later use to restore the gut microbiota after perturbation, such as antimi-
crobial use. Bolstering the commensal microbiome by autoFMT following exposure to
antimicrobials may be effective at combating colonization with MDROs (17). AutoFMT
theoretically has a more desirable safety proﬁle than alloFMT because the feces
originated from the participant and was collected during a healthy state. The purpose
of this study was to evaluate the effects of 5 days of amoxicillin-clavulanate (Amox-Clav)
on microbiome taxonomic composition, resistance gene content, and predicted met-
abolic capacity and the effectiveness of autoFMT versus placebo in microbiome resto-
ration.
RESULTS
Enrollment. Ten healthy participants were enrolled in the study; participant char-
acteristics are given in Table 1. Two participants experienced adverse events 30 days
postenema: one patient was treated with antimicrobials for an ear infection, and the
second was diagnosed with Helicobacter pylori infection and treated with antimicrobi-
als. Neither infection was determined to be related to Amox-Clav, autoFMT, or saline
enema. There was no difference between study groups in the number of bowel
movements per day postenema or in bowel movement consistency postenema as
measured by Bristol stool type (Mann-Whitney U, P 0.05 for all).
Taxonomic compositional analysis. Among healthy volunteers (n  10), 5 days of
Amox-Clav resulted in a signiﬁcant taxonomic shift from the enrollment composition as
measured by Bray-Curtis distance (P 0.01). The taxonomic composition across all
subjects and time points is visualized in Fig. 1 and 2. Both the autoFMT and saline
groups returned to baseline taxonomic composition by 7 days posttreatment (Bray-
Curtis distance to enrollment, P 0.05).
Major taxonomic diversity reduction (Shannon index change of at least 1) oc-
curred in three of 10 participants. Two of these shifts (in participants 5 and 8) occurred
immediately following Amox-Clav. A bloom in Bacteroidetes and reduction in Actino-
bacteria and Firmicutes contributed to the diversity loss in participant 5. A proteobac-
terial bloom and loss of Bacteroidetes and Actinobacteria appeared to drive diversity
reduction in participant 8. Both participants were randomized to the autoFMT treat-
ment group. Additionally, participant 4 experienced a reduction in diversity due to loss
TABLE 1 Demographics of study population, stratiﬁed by study group (n 10)
Variable Saline no. (%) AutoFMT no. (%)
Age (median [range]), yr 34 (24–56) 26 (25–57)
Female 2 (40) 4 (80)
Nonwhite 0 (0) 1 (20)
BMI
Underweight 1 (20) 0 (0)
Normal 2 (40) 1 (20)
Overweight 1 (20) 2 (40)
Obese 1 (20) 2 (40)
Preexisting medical conditiona 2 (40) 3 (60)
Smoker (former or current) 0 0
Alcohol use
Current 4 (80) 4 (80)
Former 1 (20) 0 (0)
Never 0 (0) 1 (20)
Special dietb 1 (20) 0 (0)
Diarrhea in the past yr 2 (40) 3 (60)
Constipation in the past yr 2 (40) 0 (0)
aHysterectomy (two subjects), migraine headaches, mild hearing loss, history of sports injuries, arthritis,
history of back surgery, history of ulcer, history of knee surgery, thyroid partial.
bVegan plus ﬁsh.
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FIG 1 Taxonomic composition over time was determined by (A) metagenomic sequencing and (B) qualitative culturomics. (C) Shannon index of diversity was
calculated using species data from metagenomic sequencing. Species composition was signiﬁcantly different after Amox-Clav by type II Adonis test of Bray-Curtis
distance (P 0.01). Themost obvious change post-Amox-Clav was a Proteobacteria bloom in subject 8. Numbers preceded by “S” at the top of columns indicate participant
identiﬁcation number.
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of Proteobacteria and Actinobacteria 7 days after autoFMT treatment. In each of these
three cases, diversity was restored by the next time point (Shannon index within 0.5 of
preshift value and restoration of reduced phyla).
Resistance gene analysis. The resistance genes detected by metagenomic se-
quencing included a wide range of common resistance genes. The resistance genes
found across the most participants were tetracycline destructases (31, 32) and efﬂux
pumps, but the total number of copies of resistance genes was dominated by beta-
lactamases. The beta-lactamases were also the mechanistic category that showed the
FIG 2 Taxonomic composition and predicted absolute abundance over time by quantitative culturomics. (A) Aerobic and (B) anaerobic cultures were
quantiﬁed. Note that the aerobic cultures were less dilute, allowing greater sensitivity but a lower upper limit of detection. Also note that the relative abundance
in Fig. 1B was calculated using growth observed at the greatest dilution for each species while here species may appear in both anaerobic and aerobic cultures.
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most change correlated with Amox-Clav treatment. As expected, the number of
beta-lactamases signiﬁcantly increased in the study cohort after use of Amox-Clav
(P 0.0017), while the count of non-beta-lactamase antimicrobial inactivation resis-
tance genes was not enriched (Fig. 3 and 4). Beta-lactamase gene levels returned to
FIG 3 Beta-lactamase genes were signiﬁcantly enriched after Amox-Clav (two-tailed t test, P 0.0017). Participants randomized to autoFMT (red) and saline
(gray) both returned to baseline by day 90. Participant numbers are noted at the beginning and end of each line.
FIG 4 Enrichment of resistance genes by mechanism was determined by comparing normalized counts
(RPKM) post-Amox-Clav to enrollment. Beta-lactamases (black) were most enriched and formed a majority of
the antibiotic inactivation enzymes enriched. Efﬂux pumps were also enriched, and functional metagenomic
selections suggest cooccurrence of beta-lactamases and efﬂux pumps on a mobile element.
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baseline (not signiﬁcantly different from enrollment level) in both the saline (P 0.05)
and autoFMT (P 0.05) groups. The participants who experienced phylogenetic per-
turbation following Amox-Clav (participants 4, 5, and 8) had enriched beta-lactamase
gene content following Amox-Clav treatment. Notably, these participants did not
exhibit a common set of resistance genes enriched at enrollment (see Fig. S1 in the
supplemental material), indicating that there is not a speciﬁc set of genes at enrollment
predisposing participants to later taxonomic perturbation. The baseline beta-lactamase
composition for participants 4 and 8 ranked in the middle of all enrollment samples.
However, participant 5 exhibited the highest baseline beta-lactamase content.
Functional metagenomic selections also provided information about gene cooccur-
rence. Genes encoding the beta-lactamase CblA and an efﬂux pump from the AcrB
family cooccurred on 22 different functional metagenomic contigs in eight different
selections. Twelve such cooccurrences had exactly 114 bp between the genes, indicat-
ing a conserved multigene cassette.
Metabolic capacity analysis. Metabolic capacity of the microbiome shifted signif-
icantly following Amox-Clav, even when subjects with broad phylogenetic differences
post-Amox-Clav (participants 5 and 8) were excluded. In order to assess metabolic
perturbations, we structured an index of metabolic capacity (IMC) from the metag-
enomic sequencing data. Genes with metabolic functions were grouped into 37
functional categories. Principal-coordinate analysis of IMC (Fig. 5) demonstrated an
effect of Amox-Clav on metabolic capacity. IMC of postantimicrobial samples clusters
apart from baseline IMC. The Bray-Curtis distance between baseline and postantimi-
crobial IMC was signiﬁcantly different by type II Adonis (P 0.01). This remained true
when we excluded participants with obvious taxonomic shifts at these time points
(participants 5 and 8) to control for intrinsic metabolic differences between phyla
(P 0.01). Additionally, both saline and autoFMT groups returned to baseline compo-
sition (not signiﬁcantly different from enrollment) by day seven posttreatment (P 0.99
and P 0.84, respectively).
Thirteen of the 37 metabolic categories comprising the IMC drove the change in
metabolic capacity from enrollment to post-Amox-Clav. Each of these metabolic path-
FIG 5 Principal coordinate analysis (PCA) of metabolic pathway data (IMC) from participants without obvious taxonomic disturbances (all
participants excluding 5 and 8). IMC was derived from metagenomic sequencing data. Normally distributed conﬁdence ellipses are shown.
Post-Amox-Clav samples have signiﬁcantly different IMCs than enrollment samples by type II Adonis test of Bray-Curtis distance (P 0.01). This
is true with or without participants 5 and 8. IMC returned to baseline state by 90 days with saline or autoFMT at similar rates.
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way categories was enriched post-Amox-Clav. Factors and their relative contribution
are found in Fig. S2 and are ranked according to their contribution to this difference in
Table S1. AutoFMT did not affect IMC differently than the saline control. IMC returned
to baseline state by 30 days with saline or autoFMT. Saline or autoFMT did not result in
different rates of return to baseline IMC. We found signiﬁcant differences between
individual participants’ IMCs when all time points were compared by type II Adonis
(P 0.01).
DISCUSSION
This pilot study evaluated the impact of Amox-Clav on the taxonomic function,
resistome, and metabolic potential of the microbiome, and whether autoFMT could
reverse any changes. Analysis of antimicrobial perturbation of the gut microbiome is
complicated by the wide variation between baseline taxonomic compositions of
healthy guts (33, 34), Additionally, while antimicrobial use has been demonstrated to
reduce species diversity and cause diarrhea, the speciﬁc taxonomic changes observed
vary greatly by individual (33).
Despite the dramatic and rapid perturbations observed acutely following antimi-
crobial exposure, surprising longer-term robustness and resilience have been previ-
ously observed. Most pilot studies and case reports after amoxicillin or ciproﬂoxacin
indicate return to baseline by two months after exposure (33–36). However, while
overall diversity and structure may be restored, some species remain missing. These
analyses have been limited by resolution of 16S ribotype data and have been unable
to detect resistance and metabolic genes. These factors may play critical roles in
determining the robustness of the restructured microbiome to antimicrobial perturba-
tion and pathogen invasion. Using shotgun sequencing, we tracked resistance and
metabolic genes not detectable in previous 16S analyses of taxonomy.
Among healthy volunteers, 5 days of Amox-Clav exposure (875 mg BID) led to
signiﬁcant taxonomic shifts (P 0.01), beta-lactamase gene enrichment (P 0.0017),
and predicted metabolic capacity alteration (P 0.01). Interestingly, only two partici-
pants demonstrated obvious phylum-level taxonomic perturbation of the type readily
detected by traditional analysis. However, Amox-Clav led to enrichment of 13 metabolic
gene categories and signiﬁcant alteration from enrollment. This signiﬁcant shift in
metabolic capacity was observed even in the absence of phylum-level differences.
Considering that interindividual intestinal microbiome metabolic potential is more
homogeneous in contrast to the interindividual phylogenic heterogeneity (37),
antimicrobial-induced alterations in functional metabolic potential may be more im-
portant than taxonomic alterations when predicting acquisition and/or proliferation of
an MDRO.
This study’s limitations included small sample size and limited taxonomic perturba-
tion following Amox-Clav. In addition, the most obvious taxonomic shifts occurred in
participants randomized to autoFMT. These factors limited assessment of autoFMT’s
effects on taxonomic restoration. However, this provided an opportunity to assess
metabolic perturbation in the absence of broad taxonomic shifts. Small sample size
limited our ability to assess the implications of the observed shift in metabolic capacity.
Future work is necessary to explore perturbations caused by more disruptive antimi-
crobial regimens and the ability of autoFMT to restore gut phylogeny.
This study assessed the effects of the dose of Amox-Clav consistent with clinical dosing
and previous studies where gut dysbiosis was observed (38). This drug and dose are
clinically relevant given UTI and community-acquired pneumonia treatment recommen-
dations. Future work should assess the effects of antimicrobial protocols predicted to result
in greater perturbation. In addition, methodological variations for FMT should be tested.
The European Society for Clinical Microbiology and Infectious Diseases for FMT treatment
of C. difﬁcile infection recommends using 30 g of stool in 150ml of saline (39). Although
100ml of autoFMT product was administered in this study, 50 g of stool was used. Whether
the volume administered and/or amount of stool used to create the FMT product and/or
route of administration matters needs to be determined.
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Despite these limitations, this study contributes to our understanding of the gut
microbiome in several important ways. This study supports the concept of the healthy
microbiome’s resilience following perturbation. AutoFMT was found to be safe and well
tolerated, with no adverse events. By 7 days following Amox-Clav phylogeny, beta-
lactamase content and predicted metabolic capacity returned to baseline.
Most strikingly, this study demonstrates the importance of assessing gut metabolic
potential, which was signiﬁcantly altered even in the absence of taxonomic shifts. This
shift in metabolic capacity can be detected only using shotgun sequencing or metab-
olite proﬁling. Further work is necessary to determine the implications of this shift in
metabolic capacity on risk of MDRO colonization and host metabolism.
MATERIALS AND METHODS
Overview. This was a prospective, randomized controlled pilot study (NCT 02046525) to determine
the effect of autoFMT on the intestinal microbiome versus placebo (saline enema) after 5 days of
Amox-Clav, administered at 875 mg twice per day. The study participants and investigators were blinded
to the treatment assignment until after all analyses were completed. This study was approved by the
Washington University School of Medicine Human Research Protection Ofﬁce. Written informed consent
was obtained from all study participants.
Study participants. Ten healthy volunteers were recruited to participate. Written informed consent
was obtained from all study participants. Inclusion criteria included being generally healthy and between
21 and 70 years of age. Exclusion criteria included a history of allergic reaction to beta-lactam antimi-
crobials or contraindications to amoxicillin-clavulanic acid; any nontopical antimicrobial exposure or tube
feeds as a primary source of nutrition in the six months prior to enrollment; pregnancy or risk of
becoming pregnant during the study period; gastroenteritis in the last three months; any nonelective
hospitalization in the previous 12 months; incontinency of feces; prior resection or alteration of the
stomach, small bowel, or colon; unwillingness to receive an enema/FMT; known colonization with an
MDRO; anticipated change in diet, medications, or elective surgery during the study period; or a history
of an intestinal disorder.
Study procedures. Participants submitted stool samples to study investigators at enrollment,
immediately post-Amox-Clav, and at days 1, 7, 30, and 90 postenema. Once the preantimicrobial
specimen was obtained, the participant was instructed to take 5 days of Amox-Clav at 875 mg twice daily
(BID). Participants were requested to return the bottles of Amox-Clav to conﬁrm all doses had been taken.
The participant was then randomized in a 1:1 fashion to 100 ml of placebo (nonbacteriostatic saline) or
autoFMT product. The autoFMT product was thawed overnight at room temperature. The study enema
was administered 24 to 48 h after the last dose of Amox-Clav. The participants were instructed to retain
the material for as long as possible. All participants retained 90% of the material. Study participants
were monitored for 30 min after the enema. Previous studies in FMT for treatment of C. difﬁcile infection
have demonstrated that FMT effectiveness is not dependent on FMT volume (40). In order to maintain
blinding of the study participant, the study enema was delivered to the study clinic in an opaque bag,
and the participant was instructed to not turn around when the enema was being prepared and
administered. A vial of the participant’s autoFMT product was opened in the room, regardless if
randomized to placebo or autoFMT, prior to preparing the enema for administration in order to prevent
the participant from attempting to guess which study group she or he had been assigned to based on
the odor during the procedure. The investigators doing the sequencing work remained blinded to the
study group until after the sequencing was completed.
Fecal processing. Participants were provided with sealable feces collection devices. After the
participant collected a bowel movement, samples were delivered within 2 h of collection. Upon receipt,
the feces was immediately processed with 1.5 g reserved for feces culture, 1 g for Clostridium difﬁcile
culture, and approximately 23 g for feces pulverization and sequence-based analyses, and 50 g of the
subject’s ﬁrst sample was used to prepare the FMT product.
FMT product preparation. To prepare the FMT product, approximately 50 g of feces was weighed
and transferred to a sterile container. Nonbacteriostatic saline was added to the feces in a volume of
twice the weight of the feces. A sterile spatula was used to emulsify the mixture for 3 to 5 min. Then the
mixture was allowed to rest for 5 min. The feces-saline mixture was then poured through a stainless steel
strainer to remove large particulate matter. Four 2-ml aliquots were frozen for genomic analysis of the
stored FMT product. The remaining ﬁltrate was drawn into 60-ml syringes (50 ml ﬁltrate each). If the
patient was randomized to saline, two 60 -ml syringes were ﬁlled with nonbacteriostatic saline. The ﬁlled
syringes and aliquots were stored at 80°C.
Quantitative culturomics. Fresh feces (1.5 g) was added to an equal amount of 1 PBS and mixed
thoroughly. Immediately, six 10-fold serial dilutions were made from the homogenized specimen. Ten
microliters and 100 l of the 1/10 and 1/100 dilutions were plated to two each of the following media:
TSA II with 5% sheep blood (BAP; BBL BD, Franklin Lakes, NJ), Columbia colistin nalidix agar with 5%
sheep blood (CNA; BBL BD), MacConkey (MAC; BBL BD), and chocolate agar (CHOC; BBL BD). The BAP and
CHOC were incubated at 35°C in CO2. The CNA and MAC were incubated at 35°C in air. The plates were
read at 24 h and 72 h. Ten microliters and 100 l of the 1/103 and 1/106 dilutions were plated to two each
of the following media: brucella blood agar (BBA; Anaerobe Systems, Morgan Hill, CA), Bacteroides bile
esculin agar (BBE; Anaerobe Systems), laked blood with kanamycin and vancomycin (LKV; Anaerobe
Systems), cycloserine-cefoxitin fructose agar with horse blood and taurocholate (CCFA_HT; Anaerobe
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Systems), and phenylethyl alcohol blood agar (PEA; Anaerobe Systems). These plates were incubated at
35°C anaerobically for 7 days. The plates were read at 48 h, 4 to 5 days, and 7 days. One gram of fresh
feces was processed for culture of C. difﬁcile, as previously described (41).
All growth was observed and recorded semiquantitatively. All distinct colonies were identiﬁed using
Vitek MS IVD v2.0 MALDI-TOF MS (bioMérieux). For any isolate that was not identiﬁed, a Gram stain was
performed. All isolates were stored in TSB with glycerol at 80°C.
Metagenomic DNA extraction and sequencing. Metagenomic DNA was extracted from 0.5 g of
feces via phenol-chloroform for each sample as previously described (18). DNA from each sample was
sheared to 500 to 600 bp using the Covaris E220 sonicator (intensity, 4; duty cycle, 10%; cycles per burst,
200; treatment time, 75 s; temperature, 4°C; sample volume, 130 l). The sonication product was puriﬁed
with the Qiagen PCR puriﬁcation kit and eluted in 63 l nuclease-free water (prewarmed at 50°C).
End repair and barcode ligation reactions were performed in triplicate for each sample. End repair
was performed in a Bio-Rad thermocycler using the following reagents: 2.5 l T4 DNA ligase buffer with
10 mM ATP (10) (NEB; B0202S), 1 l dNTP (1 mM), 0.5 l T4 polymerase (NEB; M0203S), 0.5 l T4 PNK
(NEB; M0201S), and 0.5 l Taq polymerase (NEB; M0267S).
The barcode ligation reaction was performed by adding 2.5 l of unique sequencing barcode at 1 M
to 500 ng of end-repaired DNA. An 0.8-l amount of T4 DNA ligase (NEB; M0202M) was incubated with
the barcode and sample DNA mixture in a Bio-Rad thermocycler. Following barcode ligation, samples
were pooled into groups containing 6 barcodes. Pools were puriﬁed using the Qiagen PCR puriﬁcation
kit and MinElute columns and eluted in 15 l of EB.
Fragment size selection was performed using a Use 0.5 TBE 1.5% agarose gel and visualized with
SYBR Safe DNA stain. Barcoded DNA fragments sized 400 to 900 bp were cut from the gel, puriﬁed with
the Qiagen Gel Extraction kit and MinElute columns, and eluted in 12 l buffer EB. Two microliters of the
eluted mixture was used for PCR enrichment of size-selected products. The enrichment reaction was
prepared as follows: 12.5 l 2 Phusion HF Master Mix, 9.5 l nuclease-free water, 1 l Illumina PCR
primer mix (FR) (10 M), and 2 l gel-puriﬁed DNA. The reaction was performed in a Bio-Rad
thermocycler using the following program: 17 cycles of 98°C for 30 s (0:30), 65°C for 30 s (0:30), and 72°C
for 30 s (0:30); 72°C for 5 min; and 4°C forever.
Size selection of the enriched products was performed using a Use 0.5 TBE 1.5% agarose gel, and products
were visualized with SYBR Safe DNA stain. Fragments sized 400 to 900 bp were cut from the gel, puriﬁed with
the Qiagen Gel Extraction kit and MinElute columns, and eluted in 15l of EB. DNA concentration was
quantiﬁed using a Qbit ﬂuorometer, and all sample pools were combined at equal concentrations for
sequencing. Prior to sequencing, pooled fragment size was assessed with a Bioanalyzer trace and barcode
read distribution was assessed using a spike-in run on the Illumina sequencing platform.
To generate metagenomic sequencing reads, the Illumina NextSeq platform was used with the high
output kit and settings to generate a minimum of 400 million paired-end reads per run. In total, 70
samples were sequenced at least 1 million reads per sample to allow microbiome and resistome analyses.
The depth of 1 million reads was established using previous studies of the gut microbiome (42–44).
Multiplexed Illumina paired-end shotgun metagenomic sequence reads were demultiplexed by
barcode. Reads without exact match to barcode were discarded. The remaining reads were quality
ﬁltered using Trimmomatic v0.35 and parameters optimized by the Dantas lab (seed mismatches, 2;
palindrome clip threshold, 30; simple clip threshold, 10; minimum adapter length, 1; keep both reads,
TRUE; window size, 4; required quality, 20; leading, 10; trailing, 10; minimum length, 60).
Microbiome taxonomic composition prediction. Taxonomic composition was determined by
comparing unique indicator sequences from sequencing reads to clade-speciﬁc marker genes from
approximately 17,000 reference genomes using MetaPhlAn 2.6.0 (18). Analysis was performed using
metaphlan2/2.6.0 with the following parameters: –blastdb./metaphlan2/blastdb–input_type multifasta.
The difference in species diversity was calculated using the Shannon index function from the R vegan
package. The difference in species composition was calculated using Bray-Curtis distance between
samples, and signiﬁcance was tested with type II Adonis.
Resistance gene prediction. The metagenomic DNA sequence was analyzed for both known and
sequence-novel antimicrobial resistance genes using functional metagenomic selections and curated
resistance gene databases for resistance gene identiﬁcation and ShortBRED for resistance gene abun-
dance estimation (45). To supplement known resistance gene markers available via the well-curated
CARD database, markers from novel, cryptic resistance gene unique to the studied samples were
obtained by performing functional metagenomic selections on bacterial metagenomic DNA pooled by
participant (46). Functional metagenomic identiﬁcation of genes that conferred resistance to Amox-Clav
was performed as previously described (18, 47, 48) by randomly shearing metagenomic DNA from each
pool of feces into fragment libraries. These libraries were cloned into the natively pan-susceptible host
Escherichia coli DH10B using vector PZE21. For each sample, the host cells containing library fragments
were selected against amoxicillin and ampicillin at concentrations lethal to the untransformed host.
Surviving colonies were pooled, and the inserted fragments were sequenced via the Illumina MiSeq
platform (2  150 bp). Sequencing reads were assembled into contigs with the PARFUMS pipeline (49).
The contigs were searched for open reading frames with MetaGeneMark (50) and annotated by
hmmscan function of HMMER3 (51) against the Resfams core database (52), Pfams (46), and TIGRFAMS
(46). Resulting annotations were then hand curated (46) in the following manner. Selections were
excluded if 100 contigs were assembled, because this suggests a failure in the assembly or selection
since 100 unique resistance contigs are expected per selection. Within each contig, annotations were
ranked by speciﬁcity to the selective agents and lowest E value with preference given to Resfams
annotations over Pfams or TIGRFAMS. In the absence of a clear speciﬁc causative gene annotation (i.e.,
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a beta-lactamase), the two best annotations with 90% overlap were accepted. The sequences corre-
sponding to accepted annotations were then pooled with known antimicrobial resistance gene se-
quences from CARD 2017 (46). The genes were then quantiﬁed in unassembled metagenomic sequence
using the ShortBRED pipeline with a clustering identity of 1.
Metabolic pathway prediction. The metabolic potential of the fecal microbial communities was
inferred through functional potential proﬁling. The presence and abundance of metabolic pathways in
the microbial communities were assessed using HUMAnN2, which maps unassembled shotgun sequenc-
ing reads to functionally annotated species pangenomes in order to predict function (53). Default
parameters were used, and details can be found at http://huttenhower.sph.harvard.edu/humann2.
In order to assess metabolic perturbations, we implemented an index of metabolic capacity (IMC)
from the metagenomic sequencing data. To form this index, we grouped genes with metabolic functions
into 37 metabolic pathway categories using Gene Ontology (GO) terms. GO term grouping was
performed using ASaiM (54) and custom scripts. The ability of the predicted metabolic capacity to
discriminate between sample groups was visualized using principal component analysis (PCA), and
signiﬁcance was tested using type II Adonis of Bray-Curtis distance between samples. This test of
signiﬁcance was conducted with and without participants 5 and 8 to determine whether any difference
observed was driven by the large taxonomic perturbations seen in those participants. Each metabolic
category comprising the IMC was tested for contribution to the difference between enrollment and
post-Amox-Clav IMC using a Random Forests model. This was implemented using the Boruta package in
R (55). Factors were ranked according to their contribution to this difference.
Statistical analysis. Signiﬁcance of differences between taxonomic composition at baseline and
post-Amox-Clav was calculated by determining Bray-Curtis distance between the communities and using
a type II Adonis with a signiﬁcance level of P 0.05 with n 10. Signiﬁcance of differences between IMC
at enrollment and post-Amox-Clav was calculated similarly. Bray-Curtis distance between IMCs was
calculated, and a type II Adonis with a signiﬁcance level of P 0.05 with n 10 was used. Because these
are permutation tests, iteration cutoffs were set to detect signiﬁcance up to P 0.01. Saline and autoFMT
treatment group taxonomy and IMC were compared to enrollment for return to baseline comparison.
Enrichment of beta-lactamase genes in postantimicrobial samples relative to enrollment was calculated
using a two-tailed t test and a signiﬁcance level of P 0.05. This test was also applied to the comparison
between saline and autoFMT to enrollment baseline.
Index of metabolic capacity validation. To determine the likelihood of obtaining a signiﬁcant
difference in IMC between groups of microbiome samples by chance, we performed bootstrap analysis
using the Human Microbiome Project 2 (HMP2) Inﬂammatory Bowel Disease (IBD) cohort. This publicly
available data set contains 364 samples from 27 healthy participants and 375 samples from 38 ulcerative
colitis patients (UC) (56). We randomly selected 2 groups of 10 healthy samples (without replacement)
and saw a difference in IMC (P 0.05) in 39 of 1,000 such iterations. This is consistent with the
expectation that we are not likely to see a signiﬁcant difference in IMC by chance alone. Note that we
selected 10 samples for each group to mirror the autoFMT study design, where a signiﬁcant difference
in IMC (P 0.01) was noted between the 10 enrollment and 10 post-Amox-Clav samples.
Accession number(s). All nucleotide sequences generated during this study have been uploaded to
NCBI under BioProject accession no. PRJNA446061.
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